You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Proteasome inhibitor re-sensitizing molecules for treatment of refractory multiple myeloma
SBC: LEUKOGENE THERAPEUTICS INC Topic: 102Project Summary Abstract Multiple MyelomaMMis the second most common form of blood cancer and remains an incurable and deadly diseaseProteasome inhibitorPItherapy is a cornerstone in the treatment of MMbut resistance to this class of agent is an emerging challenge in the clinicNew therapeutic approaches that specifically target resistance are needed to maximize responses and ultimately produce cur ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Novel SCD1 inhibitors for treatment of cancer
SBC: MODULATION THERAPEUTICS, INC. Topic: 102Project Summary Metabolic reprogramming plays a critical role in carcinogenesisin part due its ability to promote immune suppressive properties within tumorsHoweverit is unclear whether inhibition of fatty acid metabolism in tumors affects their immunogenicityHerewe show for the first time that inhibition of stearoyl CoA desaturaseSCDthe rate limiting enzyme involved in fatty acid synthesis conver ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Development of Pirenzepine for CIPN
SBC: WinSanTor, Inc. Topic: NCIPROJECT SUMMARY Chemotherapy induced peripheral neuropathyCIPNis a debilitating condition that afflictsof cancer patients undergoing chemotherapy and limits the dose and duration of treatmentSymptoms range from sensory loss to painful neuropathy and are accompanied by electrophysiological and structural indices of nerve damageThe American Society of Clinical Oncology currently makes no recommendat ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Immersive Virtual Reality as a Tool to Improve Police Safety in Adolescents and Adults with ASD
SBC: Floreo, Inc. Topic: 103Floreo Technology proposes to develop the Police Safety Module (PSM), an innovative, immersive mobile virtual reality (VR) application designed to train police safety in adolescents and adults with autism spectrum disorder (ASD). ASD has been increasing in prevalence over recent years. While much attention has been paid to the causes and early diagnosis of ASD, there remains a clear need for effec ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
The nGoggle: A portable brain-based device for assessment of visual function deficits
SBC: NGOGGLE INC Topic: NPROJECT SUMMARY Assessment of loss of visual function outside the foveal area is an essential component of the management of numerous conditionsincluding glaucomaretinal and neurological disordersDespite the significant progress achieved with the development of standard automated perimetrySAPmany decades agoassessment of visual field loss with SAP still has significant drawbacksSAP testing is limi ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Stroke Treatment by Chemically-induced Hypothermia
SBC: JT Pharmaceuticals, Inc. Topic: 101DESCRIPTION provided by applicant Stroke is a leading cause of human death and disability in the United States while clinical therapy for acute stroke is limited and unsatisfactoy The many failures in clinical trials strongly endorse the idea that to battle this multifaceted bran disorder novel strategies that target multiple cell types and different mechanisms are needed to achieve therapeut ...
STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health -
Novel Indication for Myeloid Progenitor Use: Induction of Tolerance in Solid Organ Transplantation
SBC: Cellerant Therapeutics, Inc. Topic: NIAIDPROJECT SUMMARY State of the art techniques result inyear solid organ graft loss ofto overin cardiopulmonary organ transplantationEstablishment of donor specific immunological toleranceDSITa condition in which a recipient accepts a transplant without immunosuppressionwhile retaining the ability to fight infectionswould reduce graft loss and transplant related complicationsThe only identified metho ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Recyclable Magnetic Co C Hybrid ROMP Reagents Scavengers and Ligands
SBC: MATERIA, INC. Topic: 300DESCRIPTION provided by applicant This Fast Track Small Business Technology Transfer study between Materia Inc in Pasadena CA and the University of Kansas intends to build upon successes of our current Phase II Fast Track STTR grant R GM which ends on March Preliminary results serve as a solid foundation for this Fast Track submission entitled andquot Development of Re ...
STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health -
Compact Laser Drivers for Photoconductive Semicond
SBC: SCIENTIFIC APPLICATIONS & RESEARCH ASSOCIATES, INC. Topic: DTRA16A004For effective protection against radiated threats, it is important to understand not only the physics of the threats, but also to quantify the effects they have on mission-critical electrical systems. Radiated vulnerability and susceptibility testing requires delivery of high peak power and peak electric fields to distant targets. The most practical solution to simulate such environments on large ...
STTR Phase II 2018 Department of DefenseDefense Threat Reduction Agency -
Deriving Bone Density from Thoracic CT Scans, STTR Phase II
SBC: BDI, Inc. Topic: NIAMSABSTRACT Osteoporosis is a major cause of disability and morbidity in our populationAs many asmillion Americans have osteoporosis andmillion more have osteopeniaHoweverbone mineral densityBMDassessment does not occur in many Americans when indicated and measure currently requires a separate referral and separate imaging scan to obtain BMDThe result is that onlyof Americans who are at risk of suffe ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health